Skip to main content

Advertisement

SpringerLink
Log in

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

We investigated the effects of sitagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, on the number of circulating CD34+CXCR4+cells, a candidate for endothelial progenitor cells (EPCs), plasma levels of stromal cell-derived factor (SDF)-1α, a ligand for CXCR4 receptor and a substrate for DPP-4, and plasma levels of interferon-inducible protein (IP)-10, for a substrate for DPP-4, in patients with type 2 diabetes. We studied 30 consecutive patients with type 2 diabetes who had poor glycemic control despite treatment with metformin and/or sulfonylurea. Thirty diabetic patients were randomized in a 2:1 ratio into a sitagliptin (50 mg/day) treatment group or an active placebo group (glimepiride 1 mg/day) for 12 weeks. Both groups showed similar improvements in glycemic control. The number of circulating CD34+CXCR4+ cells was increased from 30.5 (20.0, 47.0)/106 cells at baseline to 55.5 (31.5, 80.5)/106 cells at 12 weeks of treatment with 50 mg/day sitagliptin (P = 0.0014), while showing no significant changes in patients treated with glimepiride. Plasma levels of SDF-1α and IP-10, both physiological substrates of endogenous DPP-4 and chemokines, were significantly decreased at 12 weeks of sitagliptin treatment. In conclusion, treatment with sitagliptin increased the number of circulating CD34+CXCR4+ cells by approximately 2-fold in patients with type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. T. Asahara, T. Murohara, A. Sullivan, M. Silver, R. van der Zee, T. Li, B. Witzenbichler, G. Schatteman, J.M. Isner, Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964–967 (1997)

    Article  CAS  PubMed  Google Scholar 

  2. T. Takahashi, C. Kalka, H. Masuda, D. Chen, M. Silver, M. Kearney, M. Magner, J.M. Isner, T. Asahara, Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 5, 434–438 (1999)

    Article  CAS  PubMed  Google Scholar 

  3. O.M. Tepper, R.D. Galiano, J.M. Capla, C. Kalka, P.J. Gagne, G.R. Jacobowitz, J.P. Levine, G.C. Gurtner, Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106, 2781–2786 (2002)

    Article  PubMed  Google Scholar 

  4. G.P. Fadini, M. Miorin, M. Facco, S. Bonamico, I. Baesso, F. Grego, M. Menegolo, S.V. de Kreutzenberg, A. Tiengo, C. Agostini, A. Avogaro, Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J. Am. Coll. Cardiol. 45, 1449–1457 (2005)

    Article  CAS  PubMed  Google Scholar 

  5. S.K. Ghadge, S. Mühlstedt, C. Ozcelik, M. Bader, SDF-1α as a therapeutic stem cell homing factor in myocardial infarction. Pharmacol. Ther. 129, 97–108 (2011)

    Article  CAS  PubMed  Google Scholar 

  6. A.M. Lambeir, C. Durinx, S. Scharpé, I. De Meester, Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40, 209–294 (2003)

    Article  CAS  PubMed  Google Scholar 

  7. G.P. Fadini, E. Boscaro, M. Albiero, L. Menegazzo, V. Frison, S. de Kreutzenberg, C. Agostini, A. Tiengo, A. Avogaro, The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 33, 1607–1609 (2010)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. W. Wojakowski, M. Tendera, A. Michałowska, M. Majka, M. Kucia, K. Maślankiewicz, R. Wyderka, A. Ochała, M.Z. Ratajczak, Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 110, 3213–3220 (2004)

    Article  CAS  PubMed  Google Scholar 

  9. G.P. Fadini, D. Losordo, S. Dimmeler, Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ. Res. 110, 624–637 (2012)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. A. Antonelli, S.M. Ferrari, D. Giuggioli, E. Ferrannini, C. Ferri, P. Fallahi, Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun. Rev. 13, 272–280 (2014)

    Article  CAS  PubMed  Google Scholar 

  11. Y. Aso, N. Ozeki, T. Terasawa, R. Naruse, K. Hara, M. Suetsugu, K. Takebayashi, M. Shibazaki, K. Haruki, K. Morita, T. Inukai, Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl. Res. 159, 25–31 (2012)

    Article  CAS  PubMed  Google Scholar 

  12. C.G. Egan, R. Lavery, F. Caporali, C. Fondelli, F. Laghi-Pasini, F. Dotta, V. Sorrentino, Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia 51, 1296–1305 (2008)

    Article  CAS  PubMed  Google Scholar 

  13. R. Wyderka, W. Wojakowski, T. Jadczyk, K. Maślankiewicz, Z. Parma, T. Pawłowski, P. Musiałek, M. Majka, M. Król, W. Kuczmik, S. Dworowy, B. Korzeniowska, M.Z. Ratajczak, M. Tendera, Mobilization of CD34+CXCR4+ stem/progenitor cells and the parameters of left ventricular function and remodeling in 1-year follow-up of patients with acute myocardial infarction. Mediat Inflamm. 2012, 56402 (2012)

    Google Scholar 

  14. R. Möhle, F. Bautz, S. Rafii, M.A. Moore, W. Brugger, L. Kanz, The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 91, 4523–4530 (1998)

    PubMed  Google Scholar 

  15. R&D Systems, Inc., Datasheet. Quantikine. Human CXCL12/SDF-1α immunoassay. (R&D Systems, Inc., Minneapolis, 2014), pp. 1–10

  16. M. Dettin, A. Pasquato, C. Scarinci, M. Zanchetta, A. De Rossi, C. Di Bello, Anti-HIV activity and conformational studies of peptides derived from the C-terminal sequence of SDF-1. J. Med. Chem. 47, 3058–3064 (2004)

    Article  CAS  PubMed  Google Scholar 

  17. T. Kusuyama, T. Omura, D. Nishiya, S. Enomoto, R. Matsumoto, K. Takeuchi, J. Yoshikawa, M. Yoshiyama, Effects of treatment for diabetes mellitus on circulating vascular progenitor cells. J. Pharmacol. Sci. 102, 96–102 (2006)

    Article  CAS  PubMed  Google Scholar 

  18. G.P. Fadini, A. Avogaro, Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. Atherosclerosis 229, 23–97 (2013)

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

All authors have read the journal’s authorship agreement.

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, Dokkyo Medical University, 880 Kita-Kobayashi, Shimotsuga, Mibu, Tochigi, 321-0293, Japan

    Yoshimasa Aso, T. Jojima, T. Iijima & K. Suzuki

  2. Department of Internal Medicine, Koshigaya Hospital, Dokkyo Medical University, Koshigaya, Saitama, Japan

    T. Terasawa, K. Hara, K. Takebayashi & T. Inukai

  3. LSI Medience Corp., Itabashi-Ku, Tokyo, Japan

    M. Fukushima & A. Momobayashi

  4. Department of Medicine, Ishibashi General Hospital, Shimotsuke, Tochigi, Japan

    K. Kasai

Authors
  1. Yoshimasa Aso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Jojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Iijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Terasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Fukushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Momobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K. Takebayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K. Kasai
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T. Inukai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshimasa Aso.

Ethics declarations

Conflict of interest

All authors have read the journal’s policy on conflicts of interest and have none to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aso, Y., Jojima, T., Iijima, T. et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes. Endocrine 50, 659–664 (2015). https://doi.org/10.1007/s12020-015-0688-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-015-0688-5

Keywords

Search

Navigation